Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma
10.11817/j.issn.1672-7347.2018.04.009
- VernacularTitle:立体定向放射治疗联合替莫唑胺治疗复发性脑胶质瘤的疗效
- Author:
Huiping ZHAO
1
;
Sha LIU
;
Chengchuan JIANG
;
Xiangjun LI
;
Sanyuan TANG
Author Information
1. 湖南省脑科医院肿瘤科
- Keywords:
brain glioma;
recurrence;
stereotactic radiotherapy;
temozolomide;
clinical efficacy
- From:
Journal of Central South University(Medical Sciences)
2018;43(4):394-397
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma.Methods:A total of 36 patients with recurrent glioma were retrospectively analyzed and divided into a control group (n=12),who received stereotactic radiation therapy,and an experimental group (n=24),who received stereotactic radiation therapy plus temozolomide.The clinical efficacy and adverse reactions for the 2 groups were compared.Results:Total effective rate and local control rate for clinical treatment were 66.67% and 93.94%,respectively.Late adverse reaction was not observed.The effective rate and local control rate in the experimental group were 77.27% and 95.45%,which were slight higher than those in the control group,with no statistical significance (P>0.05).The 0.5-,1-,2-,3-year follow-up total survival rates were 90.91%,63.64%,42.42%,and 15.15%,respectively.The 0.5-,1-,2-,3-year follow-up survival rates in the experimental group were 95.45%,72.72%,54.54% and 22.73%,respectively,while those in the control group were 81.82%,45.45%,18.18%,and 0%,respectively.Survival analysis showed the survival time for the experimental group was significantly longer than that of the control group (30.00 months vs 14.00 months,P=0.010).Conclusion:Stereotactic radiation therapy combined with temozolomide for recurrent glioma is effective,and it has positive effect on improving the clinical efficacy and survival rate for the patients.